Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>
Pioneering Brand with a Defensible Niche: Fancl is a pioneer in preservative-free cosmetics and supplements, a concept born from addressing skin problems caused by additives in the 1970s. This focus on "Mutenka"(additive-free) products creates a strong brand identity and appeals to a loyal base of health and safety-conscious consumers.</li>
 <li>
Strategic Shift Towards Brand Empathy and Overseas Growth: Recognizing that functional value alone is no longer sufficient in a competitive market, management is executing a strategic shift to build a stronger brand image that fosters emotional connection with customers. Concurrently, the company is aggressively targeting overseas markets, particularly China's growing supplement sector, as a primary growth driver.</li>
 <li>
Synergistic Partnership with Kirin Holdings: The capital and business alliance with Kirin Holdings presents significant synergistic opportunities. This partnership is expected to enhance R&amp;D capabilities, expand market presence, and accelerate growth in the health science domain, aiming to make Fancl a leading health science company in the Asia-Pacific region.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Pioneering Brand with a Defensible Niche: Fancl is a pioneer in preservative-free cosmetics and supplements, a concept born from addressing skin problems caused by additives in the 1970s. This focus on "Mutenka"(additive-free) products creates a strong brand identity and appeals to a loyal base of health and safety-conscious consumers.
  
Strategic Shift Towards Brand Empathy and Overseas Growth: Recognizing that functional value alone is no longer sufficient in a competitive market, management is executing a strategic shift to build a stronger brand image that fosters emotional connection with customers. Concurrently, the company is aggressively targeting overseas markets, particularly China's growing supplement sector, as a primary growth driver.
  
Synergistic Partnership with Kirin Holdings: The capital and business alliance with Kirin Holdings presents significant synergistic opportunities. This partnership is expected to enhance R&amp;D capabilities, expand market presence, and accelerate growth in the health science domain, aiming to make Fancl a leading health science company in the Asia-Pacific region.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>I tally 50 - mostly firm, mostly Asia-Pac - transactions currently being discussed and analysed on Smartkarma. Inside is a timetable of upcoming key events for each deal.</li>
<li>Three new deals discussed this week: <a href="https://www.smartkarma.com/entities/fancl-corp" target="_blank" data-smartkarma-citation="entities:15862:1" rel="noopener">Fancl (4921 JP)</a>'s Tender offer, <a href="https://www.smartkarma.com/entities/a8-new-media-group-ltd" target="_blank" data-smartkarma-citation="entities:3444:1" rel="noopener">A8 New Media (800 HK)</a>'s Scheme, and <a href="https://www.smartkarma.com/entities/jeisys-medical-inc" target="_blank" data-smartkarma-citation="entities:36766:1" rel="noopener">Jeisys Medical (287410 KS)</a>'s delisting offer. Bain also approached <a href="https://www.smartkarma.com/entities/bapcor-ltd" target="_blank" data-smartkarma-citation="entities:8433:1" rel="noopener">Bapcor (BAP AU)</a>.</li>
<li>Key updates took place on: <a href="https://www.smartkarma.com/entities/sigma-healthcare-ltd" target="_blank" data-smartkarma-citation="entities:15966:1" rel="noopener">Sigma Healthcare (SIG AU)</a>, <a href="https://www.smartkarma.com/entities/alumina-ltd" target="_blank" data-smartkarma-citation="entities:939:1" rel="noopener">Alumina (AWC AU)</a>, <a href="https://www.smartkarma.com/entities/greatview-aseptic-packaging" target="_blank" data-smartkarma-citation="entities:10802:1" rel="noopener">Greatview Aseptic Packaging (468 HK)</a>, <a href="https://www.smartkarma.com/entities/helios-techno-holding-co-ltd" target="_blank" data-smartkarma-citation="entities:13934:1" rel="noopener">Helios Techno (6927 JP)</a>, and <a href="https://www.smartkarma.com/entities/tatsuta-electric-wire-cable-co-ltd" target="_blank" data-smartkarma-citation="entities:12509:1" rel="noopener">Tatsuta Electric Wire &amp; Cable (5809 JP)</a>.</li>
</ul>


I tally 50 - mostly firm, mostly Asia-Pac - transactions currently being discussed and analysed on Smartkarma. Inside is a timetable of upcoming key events for each deal.
Three new deals discussed this week: Fancl (4921 JP)'s Tender offer, A8 New Media (800 HK)'s Scheme, and Jeisys Medical (287410 KS)'s delisting offer. Bain also approached Bapcor (BAP AU).
Key updates took place on: Sigma Healthcare (SIG AU), Alumina (AWC AU), Greatview Aseptic Packaging (468 HK), Helios Techno (6927 JP), and Tatsuta Electric Wire &amp; Cable (5809 JP).


(Mostly) Asia-Pac M&A: Fancl, Jeisys Medical, A8 New Media, Bapcor, Helios Techno,Tatsuta Electric

Travis Lundy

<ul>
<li>
<a href="https://www.smartkarma.com/entities/kirin-holdings-co-ltd" target="_blank" data-smartkarma-citation="entities:16977:1" rel="noopener">Kirin Holdings (2503 JP)</a> bought a 33% stake from the founder and several others in August 2019. Five years later, they are coming back for the rest. </li>
<li>The price here is ¥2,690/share which is a 42.7% premium from yesterday's close. Kirin paid 20+% more in 2019. Earnings fell, but they paid 37x NTM. This is 32x. </li>
<li>This is lightish... but...  this should get done. Activism would be difficult. There are enough shareholders who should be OK getting out. This should trade tight.</li>
</ul>



Kirin Holdings (2503 JP) bought a 33% stake from the founder and several others in August 2019. Five years later, they are coming back for the rest. 
The price here is ¥2,690/share which is a 42.7% premium from yesterday's close. Kirin paid 20+% more in 2019. Earnings fell, but they paid 37x NTM. This is 32x. 
This is lightish... but...  this should get done. Activism would be difficult. There are enough shareholders who should be OK getting out. This should trade tight.


Fancl (4921) TOB - Kirin (2503) Does the Inevitable and Takes Out Minorities. Lightish But...

Analyst

Steve

<ul>
<li>
<a href="https://www.smartkarma.com/entities/fancl-corp" target="_blank" data-smartkarma-citation="entities:15862:1" rel="noopener">Fancl Corp (4921 JP)</a>'s share price has declined 18% year-to-date, greatly under-performing the <a href="https://www.smartkarma.com/entities/nikkei-225" target="_blank" data-smartkarma-citation="entities:22909:1" rel="noopener">Nikkei 225 (NKY INDEX)</a> which was up 17% year-to-date. </li>
<li>The company recently announced FY24 results (fiscal year ending March).  Sales grew 7% yoy and operating profit grew 60% yoy in FY24. </li>
<li>I believe the stock price is attractive at 23x 2024 PE with 15% expected earnings CAGR for the next 3 years.</li>
</ul>



Fancl Corp (4921 JP)'s share price has declined 18% year-to-date, greatly under-performing the Nikkei 225 (NKY INDEX) which was up 17% year-to-date. 
The company recently announced FY24 results (fiscal year ending March).  Sales grew 7% yoy and operating profit grew 60% yoy in FY24. 
I believe the stock price is attractive at 23x 2024 PE with 15% expected earnings CAGR for the next 3 years.


Fancl (4921 JP):  Worth A Bet Given Negative Impact Of Kobayashi Products Recall Subsiding

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

iShares MSCI ACWI ex US ETF / Technical Analysis

<ul>
<li>Many major indexes have broken below critical supports, including MSCI ACWI (ACWI-US), EURO STOXX 50, STOXX Europe 600, and the DAX.</li>
<li>Odds suggest a bearish downside continuation, and a bearish outlook is appropriate as long as the YTD downtrend remains intact on the ACWI-US, MSCI ACWI ex-US (ACWX-US), and EAFE (EFA-US).</li>
<li>There is bounce potential given these broad global indexes are testing their respective downtrend channel supports, but the fact remains that they are in downtrends, a major problem longer-term.</li>
</ul>


Many major indexes have broken below critical supports, including MSCI ACWI (ACWI-US), EURO STOXX 50, STOXX Europe 600, and the DAX.
Odds suggest a bearish downside continuation, and a bearish outlook is appropriate as long as the YTD downtrend remains intact on the ACWI-US, MSCI ACWI ex-US (ACWX-US), and EAFE (EFA-US).
There is bounce potential given these broad global indexes are testing their respective downtrend channel supports, but the fact remains that they are in downtrends, a major problem longer-term.


MSCI ACWI Ex-US, EAFE Testing Downtrend Channel Supports -- Bounce Potential

Japan

FANCL CORPORATION produces and sells additive-free skin care cosmetics for both women and men.  The Company's products include cleansing creams, hair care goods such as shampoos and conditioners, and facial make up products.  Fancl also makes and distributes dietary supplements including royal jelly and various tablets with extracted essence from mushrooms, garlic, ginseng, and soy beans.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Fancl Corp (4921 JP)

Primer: Fancl Corp (4921 JP) - Aug 2026

Pioneering Brand with a Defensible Niche: Fancl is a pioneer in preservative-free cosmetics and supplements, a concept born from addressing...

αSK Primers

(Mostly) Asia-Pac M&A: Fancl, Jeisys Medical, A8 New Media, Bapcor, Helios Techno,Tatsuta Electric

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

David Blennerhassett

Fancl (4921) TOB - Kirin (2503) Does the Inevitable and Takes Out Minorities. Lightish But...

Kirin has arrived to take out minorities in Fancl (4921). This was to be expected eventually. Slightly opportunistic in the big picture. But not an...

Travis Lundy

Fancl (4921 JP): Worth A Bet Given Negative Impact Of Kobayashi Products Recall Subsiding

Good timing - Kirin Holdings will launch a tender offer for Fancl, turning the Japanese maker of skin care products and dietary supplements into a...

Steve

MSCI ACWI Ex-US, EAFE Testing Downtrend Channel Supports -- Bounce Potential

Bounce potential given $ACWX $EFA testing downtrend channel supports, but it would likely be a short-term trading opportunity due to the fact that...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)